Objective: To evaluate the long-term efficacy and safety of guselkumab for the treatment of moderate-to-severe psoriasis.
VOYAGE 1 is an on-going, phase 3, randomized, double-blinded, placebo- and active comparator- controlled trial.
The study consisted of the blinded treatment period, which comprised the placebo-controlled period (weeks 0–16) and
the active comparator-controlled period (weeks 0–48; guselkumab versus adalimumab), and the open-label extension
period (starting at week 52 and on-going). At baseline, 837 patients were randomized (2:1:2) to receive either:
(1) guselkumab 100mg at weeks 0, 4, and 12 and then every-8-weeks;
(2) placebo at weeks 0, 4, and 12 with crossover to guselkumab 100mg at weeks 16/20 and then every-8-weeks; or
(3) adalimumab 80mg at week 0, 40mg at week 1 followed by every-2-week dosing through week 47, with crossover to
guselkumab 100mg every- 8-weeks at week 52 (adalimumab to guselkumab). Starting at week 52, all eligible patients
continued open-label guselkumab treatment every-8-weeks through week 204.